English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

There is an increasing number of potential biomarkers that could allow forearly assessment of treatment response or disease progression. However,measurements of quantitative biomarkers are subject to random variability.Hence, differences of a biomarker in longitudinal measurements do notnecessarily represent real change but might be caused by this randommeasurement variability. Before utilizing a quantitative biomarker inlongitudinal studies, it is therefore essential to assess the measurementrepeatability. Measurement repeatability obtained from test-retest studies canbe quantified by the repeatability coefficient (RC), which is then used in thesubsequent longitudinal study to determine if a measured difference representsreal change or is within the range of expected random measurement variability.The quality of the point estimate of RC therefore directly governs theassessment quality of the longitudinal study. RC estimation accuracy depends onthe case number in the test-retest study, but despite its pivotal role, nocomprehensive framework for sample size calculation of test-retest studiesexists. To address this issue, we have established such a framework, whichallows for flexible sample size calculation of test-retest studies, based uponnewly introduced criteria concerning assessment quality in the longitudinalstudy. This also permits retrospective assessment of prior test-retest studies.

A statistical framework for planning and analysing test-retest studies for repeatability of quantitative biomarker measurements